{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:10:35Z","timestamp":1767841835403,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.gastha.2023.11.016","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T01:40:30Z","timestamp":1701913230000},"page":"417-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial"],"prefix":"10.1016","volume":"3","author":[{"given":"Yuval","family":"Ishay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Neutel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yotam","family":"Kolben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Gelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orly Sneh","family":"Arbib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Katchman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwana","family":"Mohseni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Kidron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-1220","authenticated-orcid":false,"given":"Yaron","family":"Ilan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2023.11.016_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","volume":"22","author":"Huby","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.gastha.2023.11.016_bib2","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2023.11.016_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.597648","article-title":"Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies","volume":"11","author":"Luci","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.gastha.2023.11.016_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13695","article-title":"Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis","volume":"52","author":"Guerra","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.gastha.2023.11.016_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cld.2009.07.009","article-title":"Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis","volume":"13","author":"Cusi","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gastha.2023.11.016_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/pr9010135","article-title":"Non-alcoholic fatty liver disease: from pathogenesis to clinical impact","volume":"9","author":"Caturano","year":"2021","journal-title":"Processes"},{"key":"10.1016\/j.gastha.2023.11.016_bib7","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2174\/138161210791208875","article-title":"Insulin resistance in nonalcoholic fatty liver disease","volume":"16","author":"Bugianesi","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.gastha.2023.11.016_bib8","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1038\/s41467-022-35310-5","article-title":"Upper gut heat shock proteins HSP70 and GRP78 promote insulin resistance, hyperglycemia, and non-alcoholic steatohepatitis","volume":"13","author":"Angelini","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastha.2023.11.016_bib9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.mayocp.2022.04.005","article-title":"Nonalcoholic fatty liver disease: review of management for primary care providers","volume":"97","author":"Basu","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.gastha.2023.11.016_bib10","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.3748\/wjg.v28.i35.5129","article-title":"Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis","volume":"28","author":"Suri","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastha.2023.11.016_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.742382","article-title":"Non-alcoholic steatohepatitis pathogenesis, diagnosis, and treatment","volume":"8","author":"Zhu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.gastha.2023.11.016_bib12","first-page":"296","article-title":"Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment","volume":"31","author":"Ilan","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.gastha.2023.11.016_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/apt.14210","article-title":"Review article: new treatments in non-alcoholic fatty liver disease","volume":"46","author":"Townsend","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2023.11.016_bib14","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.4254\/wjh.v14.i9.1718","article-title":"Therapies for non-alcoholic fatty liver disease: a 2022 update","volume":"14","author":"Shen","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.gastha.2023.11.016_bib15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.gastha.2023.11.016_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12967-021-02729-1","article-title":"Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD","volume":"19","author":"Jensen","year":"2021","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.gastha.2023.11.016_bib17","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1111\/dom.14499","article-title":"Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"23","author":"Eldor","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.gastha.2023.11.016_bib18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/dom.14901","article-title":"Oral insulin (ORMD-0801) in type 2 diabetes mellitus: a dose-finding 12-week randomized placebo-controlled study","volume":"25","author":"Eldor","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.gastha.2023.11.016_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-0716-2128-8_18","article-title":"Analysis of insulin resistance in nonalcoholic steatohepatitis","volume":"2455","author":"Kim","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.gastha.2023.11.016_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059524","article-title":"Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study","volume":"8","author":"Eldor","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gastha.2023.11.016_bib21","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/s41374-022-00807-6","article-title":"A\u00a0diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis","volume":"102","author":"Sakuma","year":"2022","journal-title":"Lab Invest"},{"key":"10.1016\/j.gastha.2023.11.016_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3803\/EnM.2022.1434","article-title":"The impact of insulin resistance on hepatic fibrosis among United States adults with non-alcoholic fatty liver disease: NHANES 2017 to 2018","volume":"37","author":"Bae","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.gastha.2023.11.016_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113863","article-title":"The role of insulin resistance and diabetes in nonalcoholic fatty liver disease","volume":"21","author":"Fujii","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gastha.2023.11.016_bib24","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.3390\/nu11112597","article-title":"mir-101-3p downregulation promotes fibrogenesis by facilitating hepatic stellate cell transdifferentiation during insulin resistance","volume":"11","author":"Meroni","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.gastha.2023.11.016_bib25","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1210\/clinem\/dgac660","article-title":"Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD","volume":"108","author":"Kalavalapalli","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gastha.2023.11.016_bib26","article-title":"Metabolic score for insulin resistance is inversely related to incident advanced liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"14","author":"Lee","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.gastha.2023.11.016_bib27","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.2147\/DDDT.S315724","article-title":"Non-alcoholic steatohepatitis (NASH) - a review of a crowded clinical landscape, driven by a complex disease","volume":"15","author":"Fraile","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.gastha.2023.11.016_bib28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14740338.2017.1343299","article-title":"Treatment options for nonalcoholic steatohepatitis - a safety evaluation","volume":"16","author":"Issa","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.gastha.2023.11.016_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155264","article-title":"Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: an overview and current perspectives","volume":"134","author":"Yan","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.gastha.2023.11.016_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/joim.13380","article-title":"Inflammatory and fibrotic mechanisms in NAFLD-implications for new treatment strategies","volume":"291","author":"Lee","year":"2022","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.gastha.2023.11.016_bib31","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/apt.13833","article-title":"Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression","volume":"44","author":"Ilan","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2023.11.016_bib32","doi-asserted-by":"crossref","first-page":"9765","DOI":"10.1073\/pnas.0908771107","article-title":"Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob\/ob mice","volume":"107","author":"Ilan","year":"2010","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.gastha.2023.11.016_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cei.13159","article-title":"Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH","volume":"193","author":"Ilan","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.gastha.2023.11.016_bib34","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/JLB.5RU0718-276RR","article-title":"Immune rebalancing by oral immunotherapy: a novel method for getting the immune system back on track","volume":"105","author":"Ilan","year":"2019","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.gastha.2023.11.016_bib35","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.3748\/wjg.v21.i24.7443","article-title":"Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance","volume":"21","author":"Khoury","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastha.2023.11.016_bib36","first-page":"151","article-title":"beta-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model","volume":"7","author":"Zigmond","year":"2014","journal-title":"J\u00a0Inflamm Res"},{"key":"10.1016\/j.gastha.2023.11.016_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192663","article-title":"Insulin resistance in lean and overweight non-diabetic Caucasian adults: study of its relationship with liver triglyceride content, waist circumference and BMI","volume":"13","author":"Gonzalez-Cantero","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.gastha.2023.11.016_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/jhep.2002.30692","article-title":"NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome","volume":"35","author":"Chitturi","year":"2002","journal-title":"Hepatology"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572323001930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572323001930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T23:02:05Z","timestamp":1714690925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572323001930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2772572323001930"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2023.11.016","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2023.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}